Effects of Differential Glycosylation on Filovirus Glycoprotein Immunogenicity
Technical Report,30 Jun 2015,31 Mar 2020
University of New Mexico Health Sciences Center Albuquerque United States
Pagination or Media Count:
All current filovirus vaccine platforms utilize the highly glycosylated filovirus attachment protein glycoprotein, or GP1,2 as an antigen. However, the different vaccine platforms are expressed in various cell types that endow differential glycosylation on GP1,2s, and the importance of the various types of glycosylation in promoting immunogenicity of filovirus GPs is not well known. In this project, we 1 determined N- and O-linked glycan patterns on filovirus GP1,2 expressed in mammalian, insect, and plant cells 2 determined that insect cell-generated glycosylated GP1,2s had increased in vitro immunogenicity in dendritic cells and 3 found that glycosylation of GP1,2 affected in vitro antibody and T cell responses.